在日本治疗高胆固醇血症的贝佩多酸的有效性和安全性:第二期多中心,随机,双盲,安慰剂控制,并行组,剂量确定试验
Shizuya Yamashita1, Hitomi Fujita2, Daisuke Yokota2
1Department of Cardiology, Rinku General Medical Center.
Journal of atherosclerosis and thrombosis
|March 2, 2025
概括
班佩多酸有效降低了日本高胆固醇血症患者的LDL-C,包括那些对他类药物不耐受的人. 180毫克的剂量被确定为适合第三阶段试验.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 高胆固醇血症具有显著的心血管风险,特别是在他类药物不耐受或反应不足的患者中.
- 酸酸酶 (ACL) 抑制剂代表了一种用于管理脂质疾病的新型治疗类.
研究的目的:
- 为了评估bempedoic酸在日本高胆固醇血症患者的疗效和安全性.
- 为了确定bempedoic酸的最佳剂量,在这个人群中进行第三期临床试验.
主要方法:
- 一个多中心,随机,双盲,安慰剂控制的2b期试验,涉及高胆固醇血症的日本患者.
- 患者在现有的脂质修饰疗法之外,接受了12周的bempedoic酸 (60,120或180毫克) 或安慰剂.
- 主要终点是低密度脂蛋白胆固醇 (LDL-C) 从基线到第12周的百分比变化.
主要成果:
- 与安慰剂相比,佩多酸在所有测试剂量 (120毫克: -21.9%,180毫克: -21.3%) 中显著降低了LDL-C.
- 在患有他类药物不耐受和对他类药物反应不足的患者中观察到显著的LDL-C降低.
- 贝佩多酸的不良事件发生率较高,但不依剂量,肌肉,肝脏或糖尿病相关事件较少.
结论:
- 班佩多酸在日本患者中表现出显著的疗效和良好的安全性,这些患者的LDL-C水平升高.
- 在日本的第三阶段试验中,180mg的bempedoic酸剂量被证实是适合进一步调查的.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
506
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
506
01:25Antihypertensive Drugs: Direct Renin Inhibitors
468
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
468
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
447
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
447
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
01:29Cholesterol: Significance and Regulation
496
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
496
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
568
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
568